Expanding Production Capacity and Improving and Automating Manufacturing and Inspection Processes
First written in FY2016. 8 of 14 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-05-28.
- FY2026-H1RaisedAnnual report
「In July 2025, our joint project with Teijin Regenerative Medicine Co., Ltd. was selected for the Ministry of Economy, Trade and Industry's regenerative medicine CDMO subsidy program. Through investment on the scale of several billion yen, we will expand facilities and equipment and develop human resources, aiming to increase the number of regenerative medicine product contracts from Japan and overseas.」
Regarding production capacity enhancement, the joint project with Teijin Regenerative Medicine was selected for a Ministry of Economy, Trade and Industry subsidy, giving concrete form to a large-scale plan involving investment of several billion yen, facility and equipment expansion, human resource development and an increase in contracts from Japan and overseas. - FY2025RaisedAnnual report
「As the CDMO business expands, the Teijin Group will establish a new production site and increase contract manufacturing capacity.」
We have broadened our production capacity enhancement strategy from improving and expanding existing facilities to establishing a new production site as part of the Teijin Group and increasing contract manufacturing capacity. - FY2025-H1AdvancedAnnual report
「On 17 June 2024, we submitted to the Ministry of Health, Labour and Welfare an application for partial change approval to expand the indications for JACC autologous cultured cartilage to include osteoarthritis of the knee. We are targeting a launch in the fiscal year ending March 2026 and are also preparing to strengthen our manufacturing system ahead of increased sales.」
Regarding the expansion of JACC's indication to osteoarthritis of the knee, we set a launch target for the fiscal year ending March 2026 and moved into the preparation stage for strengthening the manufacturing system ahead of increased sales. - FY2024RestatedAnnual report
「We aim to further innovate our proprietary production system, which we have been developing, by improving and optimizing production processes and expanding production facilities.」
To address fluctuations in workload and the transition to mass production, we continue to pursue greater efficiency and optimization of production processes and expansion of facilities. - FY2024-Q1AdvancedAnnual report
「In parallel, Nagoya University, the source of the technology, conducted a clinical study using the technology for acute lymphoblastic leukemia, while we worked to improve the efficiency of our in-house manufacturing process.」
Regarding production process efficiency, we advanced the efficiency of our in-house manufacturing process in parallel with the development of CAR-T cell products. - FY2022RaisedAnnual report
「By combining our track record and expertise in cell culture with Teijin's engineering capabilities, we will create production innovations aimed at automating the manufacture of autologous products and mass-producing allogeneic products, thereby achieving substantial cost reductions.」
We have expanded our production efficiency strategy to include automation of autologous product manufacturing using Teijin's engineering capabilities, mass production of allogeneic products and expansion of production facilities. - FY2020RestatedAnnual report
「In addition to completing the proprietary production system we have been developing, we aim to build innovative cell culture technologies by applying Fujifilm's strength in engineering technology.」
We continue to pursue greater efficiency and leveling of the production system, apply Fujifilm's engineering technology and build innovative cell culture technologies. - FY2019AdvancedAnnual report
「Capital expenditures for the fiscal year totaled ¥107.252 million, primarily for the installation and improvement of equipment and other facilities related to the regenerative medicine contract business.」
We installed and improved equipment and other facilities related to the regenerative medicine contract business, bringing capital expenditures for the fiscal year to ¥107.252 million. We have also disclosed investment plans for contract manufacturing equipment, research facilities, production facilities and production management systems in subsequent fiscal years. - FY2019-Q1AdvancedAnnual report
「AMED and we will enter into a commissioned research agreement for the program for developing evaluation infrastructure technologies for the industrialization of regenerative medicine, specifically the development of evaluation methods and other technologies for the industrialization of regenerative medicine. The commissioned project is titled “Development of foundational technologies for rationalizing the manufacturing method for autologous cultured cartilage products.” To rationalize the manufacturing method for regenerative medicine products, the project will automate tissue processing in JACC autologous cultured cartilage and establish an automated determination system for in-process inspections, among other activities.」
Regarding rationalization of the JACC manufacturing method, we entered into a commissioned research and development agreement with AMED covering 1 April 2018 to 31 March 2019 and are advancing automation of the tissue-processing process and establishment of an automated determination system for in-process inspections. - FY2018AdvancedAnnual report
「The project to develop foundational technologies for rationalizing the manufacturing method for JACC autologous cultured cartilage was selected on 28 February 2018 under the National Research and Development Agency Japan Agency for Medical Research and Development (AMED) program for developing evaluation infrastructure technologies for the industrialization of regenerative medicine, for which we had applied. Accordingly, we will accelerate activities in FY2018 to rationalize JACC manufacturing.」
The AMED project aimed at rationalizing the JACC manufacturing method was selected, moving us into the stage of accelerating manufacturing rationalization activities in FY2018. - FY2017-Q2AdvancedAnnual report
「Under the FY2016 New Aichi Creation Research and Development Subsidy Program, our project to research and develop automation of the cell isolation process was selected for funding. Under the FY2016 Robot Introduction Demonstration Project, our project to introduce robots into the cell culture process for regenerative medicine products was also selected. By using these subsidies and other funding to incorporate automation systems into the production of regenerative medicine products, we will further stabilize quality and improve production efficiency.」
Two projects, research into automating the cell isolation process and introducing robots into the cell culture process, were selected for funding, giving concrete form to the introduction of automation systems into the production process. - FY2016First statedAnnual report
「To increase manufacturing capacity for growth in the JACC autologous cultured cartilage business, we expanded the production facility on the fourth floor of our head office building. Because make-to-order production causes fluctuations in workload in the manufacturing division, resulting in inefficient use of equipment and personnel, we are promoting greater efficiency and automation in manufacturing and inspection operations.」
We expanded the production facility on the fourth floor of our head office building and are improving and automating processes to address fluctuations in operating levels caused by make-to-order production.